GENE ONLINE|News &
Opinion
Blog

2025-12-01|

Study Explores Barriers to Safe Sleep Practices in Level IV NICU Through Insights from Nurses and Parents

by GOAI
Share To

A recent study conducted in a Level IV Neonatal Intensive Care Unit (NICU) examined the implementation of safe sleep practices and gathered insights from both nursing staff and parents. Researchers Burgess, Bourque, Fisher, and their team explored this critical aspect of neonatal care through qualitative methods, focusing on how adherence to safe sleep guidelines impacts infant safety and long-term health outcomes. The study highlights perspectives from healthcare professionals and families navigating the challenges of maintaining safe sleep environments in a high-acuity NICU setting.

The research provides an in-depth look at the factors influencing compliance with safe sleep recommendations, including barriers faced by nurses and parents. It identifies key themes such as education gaps, environmental constraints within the NICU, and differing perceptions of risk among caregivers. By analyzing these insights, the study aims to inform strategies for improving safe sleep practices in neonatal care units while addressing concerns raised by both medical staff and families.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: December 1, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
LATEST
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
Janux Therapeutics Shares Halve Despite Positive Phase I Trial Results for Solid Tumor Therapy
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
Scroll to Top